ClinicalTrials.gg
CompletedNCT07884786Updated Oct 21, 2026

Effects of Myofascial Release on Postural Balance and Cervical Muscle Function in Benign Paroxysmal Positional Vertigo

An interventional study of Home-Based Balance Exercise Program and Myofascial Release Therapy in Benign Paroxysmal Positional Vertigo, sponsored by Karabuk University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Karabuk University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 1 month after the study started (first participant enrolled Sep 2021, registered Oct 2026).
Updated Oct 21, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This completed, two-arm randomized controlled trial investigated the effects of therapist-administered myofascial release added to a progressive home-based balance exercise program in individuals diagnosed with benign paroxysmal positional vertigo (BPPV). Forty participants were randomized into a home exercise group and a myofascial therapy group. Both groups followed the same six-week exercise program; the intervention group additionally received myofascial release twice weekly. Thirty-two participants completed the six-week assessment. Static balance, posture, cervical range of motion, muscle strength, and muscle activation were assessed before and after the intervention. The trial is being registered retrospectively after completion of data collection.

Read the detailed description

The study compared a six-week progressive home-based exercise program with the same program supplemented by myofascial release therapy in adults with clinically confirmed BPPV. Individuals were diagnosed by an otorhinolaryngology specialist using the Dix-Hallpike or supine Roll test, screened for eligibility and asked to provide written informed consent. Randomization was performed using random.org.

Both arms initially received instruction in exercises targeting postural balance. Movements were supervised at the first encounter, after which the weekly progression was distributed as illustrated photographs through WhatsApp. Exercises were prescribed three times per week for six weeks. In the myofascial therapy arm, a trained physiotherapist additionally delivered four techniques (single arm pull, lateral neck-shoulder, thoracic transverse-plane and anterior cervical techniques) twice a week, totaling 12 sessions. Prone techniques were avoided because some BPPV patients might experience dizziness in this position.

Assessments were performed at baseline and at the end of Week 6. Outcomes included static postural sway and stability measured using the Bertec Balance Legacy System, postural alignment measured using PostureScreenMobile, cervical range of motion measured by goniometry, cervical and scapular strength measured with a handheld dynamometer, and sternocleidomastoid and upper trapezius muscle activity measured by surface electromyography. The thesis also reports the Dynamic Gait Index, Vertigo Symptom Scale-Short Form, Dizziness Handicap Inventory, dizziness intensity, and cervical pain assessments.

This record describes a completed study originally conducted for a doctoral thesis; registration is retrospective. The date of submission to ClinicalTrials.gov is not the historical date on which participants were first enrolled.

02

Conditions studied

  • Benign Paroxysmal Positional Vertigo
03

In context

Benign Paroxysmal Positional Vertigo

75 studies on the registry are indexed under Benign Paroxysmal Positional Vertigo; 15 are open to participants now.

This study's enrollment of 40 is below the median of 75 across 61 interventional studies indexed under Benign Paroxysmal Positional Vertigo.

Browse Benign Paroxysmal Positional Vertigo studies →

Lead sponsor

Karabuk University is the lead sponsor of 132 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Complaints of positional vertigo.
  • BPPV diagnosis by Dix-Hallpike or Roll test.
  • No previous vestibular rehabilitation.
  • Ability to stand unaided on one leg for 60 seconds with eyes open.
  • Willingness to participate and provide informed consent.

Exclusion criteria

Exclusion Criteria:

  • Evidence of ear, nose or throat infection.
  • Central nervous system pathology causing dizziness.
  • Other vestibular disorders.
  • Cervical or lumbar conditions restricting exercise.
  • Meniere disease, vestibular neuritis or labyrinthitis.
  • Cardiac conditions.
  • History of headache or head trauma.
  • Lower-extremity pain, pathological conditions or surgery limiting weight-bearing or balance.
  • Vertebrobasilar insufficiency.
  • Myofascial pain syndrome.
  • Inability to cooperate with assessments.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Home Exercise Group (HEG)

    Progressive home-based balance exercise program, three days per week for six weeks, with initial supervised instruction and weekly illustrated exercise schedules provided by WhatsApp.

    Behavioral: Home-Based Balance Exercise Program

  • Experimental
    Myofascial Therapy Group (MTG)

    Identical six-week home exercise program plus physiotherapist-administered myofascial release twice weekly for six weeks (12 sessions).

    Behavioral: Home-Based Balance Exercise Program · Other: Myofascial Release Therapy

Interventions

  • BehavioralHome-Based Balance Exercise Program

    Six-week graded postural balance and vestibular exercise program prescribed three days per week. Exercises were initially practiced under supervision and then performed at home; weekly programs were delivered electronically.

  • OtherMyofascial Release Therapy

    Manual myofascial release by a trained physiotherapist involving the single arm pull, lateral neck-shoulder, thoracic transverse-plane and anterior cervical techniques; delivered twice weekly for six weeks (12 sessions).

06

What researchers measure

Primary outcomes

  1. Change in Postural Sway

    Changes in anteroposterior and mediolateral postural sway measured using the Bertec Balance Legacy System under eyes-open and eyes-closed conditions on firm and foam surfaces.

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Change in Limits of Stability

    Anterior, posterior, right, left, and total limits of stability obtained from the Bertec Balance Legacy System.

    Time frame: Baseline and Week 6

  2. Change in Postural Alignment

    PostureScreenMobile-derived anterior cervical tilt, shoulder alignment, and other posture measures; displacements reported in centimeters.

    Time frame: Baseline and Week 6

  3. Change in Cervical Range of Motion

    Active and passive cervical flexion/extension, lateral flexion and rotation assessed with a universal goniometer in degrees.

    Time frame: Baseline and Week 6

  4. Change in Cervical and Scapular Muscle Strength

    Cervical flexor/extensor and upper/middle/lower trapezius isometric force measured by dynamometry in newtons.

    Time frame: Baseline and Week 6

  5. Change in Cervical Muscle Activation by sEMG

    Right and left sternocleidomastoid and upper trapezius surface electromyography; root mean square activity in microvolts, analyzed during a 5-second maximum voluntary contraction.

    Time frame: Baseline and Week 6

  6. Change in Dynamic Gait Index Score

    Eight walking and functional gait activities, total score 0-24; higher scores indicate better performance.

    Time frame: Baseline and Week 6

  7. Change in Vertigo Symptom Scale-Short Form Score

    15-item symptom questionnaire with item responses from 0 to 4, including vestibular and anxiety-related symptom dimensions.

    Time frame: Baseline and Week 6

  8. Change in Dizziness Handicap Inventory Score

    25-item questionnaire with a total score of 0-100; higher scores indicate greater dizziness-related handicap.

    Time frame: Baseline and Week 6

  9. Change in Dizziness Severity

    Participant-reported dizziness intensity measured using a 0-10 visual analogue scale.

    Time frame: Baseline and Week 6

  10. Change in Neck Pain Severity

    Participant-reported neck pain intensity measured using a 0-10 visual analogue scale when pain is present.

    Time frame: Baseline and Week 6

07

Study locations

1 site
  • Bolu Abant Izzet Baysal University, Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Gölköy Campus
    Bolu, 14030, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in May 2023, 20 months.

Of 34 non-industry interventional studies with no phase under Benign Paroxysmal Positional Vertigo, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 37. This study's 20 months is above that.

Counting every sponsor, half of 35 studies reached it within 16 months; a quarter within 8 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Oct 21, 2026
StartActual
Sep 1, 2021
Primary completionActual
May 1, 2023
CompletionActual
May 1, 2023
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07884786
Lead sponsor
Karabuk University
Responsible party
Ece ACAR (Assistant Professor, Karabuk University) — Principal investigator
First posted
Oct 21, 2026
Start date
Sep 1, 2021
Primary completion
May 1, 2023
Completion
May 1, 2023
Last update
Oct 21, 2026

Study contacts

Ece Acar
principal investigator · Karabuk University
Tamer Çankaya
study chair · Abant Izzet Baysal University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion